This 
INTRODUCTION
There are two schools of thought regarding the use of lithium in the prophylaxis of mood disorders (Schou et al., 1982) ie. in a single once daily (OD) or in divided doses (DD). After the initial concerns about renal damage in the absence of lithium toxicity (Kassirer, 1983) , later reviews (Schou, 1988) and biopsy studies (Hetmar et al., 1991) have shown that lithium does not cause significant effects on glomerular filtration rate or renal morphology. The OD dosage school avers that this dosing improves compliance, and that the side effects related to the peak blood levels of lithium occur during sleep (Lauritsen et al., 1981) . The DD schools proposed that a more sustained, uniform level would be less damaging to the kidney.
There have been various attempts to compare OD and DD lithium dosing patterns in mood disorders. Most results have shown that the side effect profile of the OD dosage schedule is comparable to DD dosing, and that the benefits were better with OD therapy in terms of compliance (Plenge & Mellerup, 1986; Muir et al., 1989) .
In India, it is our experience that lithium is largely given in divided doses. No studies have examined OD lithium therapy. In this study, we, therefore, analyzed the benefits and risks of OD as compared with DD Lithium therapy in patients who had been prescribed lithium carbonate for the prophylaxis of mood disorders during the same period. We hypothesized that OD lithium therapy would be comparable in efficacy to DD lithium and would have relatively fewer side effects.
MATERIAL AND METHODS
Consecutive patients utilizing the inpatient and outpatient facilities of one unit of the Department of Psychiatry at the National Institute of Mental Health and Neurosciences, Bangalore,identified during a one year period, and who met DSM IIIR criteria (American Psychiatric Association, 1987) for mood disorder were selected for the study. Only patients who were on lithium for the prophylaxis of mood disorders and who were compliant on medication during the period of follow-up were included in the study.
Sixty-six patients fulfilled the criteria for the study. Out of them, 31 were on OD dosing and 35 on DD dosing schedules. The case charts of these patients were screened systematically and the data were collected using a semistructured proforma. Variables such as lithium dose, serum lithium levels, use of additional treatment, adverse drug reactions and the occurrence of further episodes were operationalized as reported by Suresh et al (1995) . Serum levels of lithium (measured by flame photometry) and side effects recorded by the treating clinician were noted. The data regarding cessation of treatment, change from one dosing pattern to another and occurrence of further episodes were also collected as recorded by the treating clinician during the period of follow up. The data available in the case charts were found sufficiently detailed for the purpose of the study.
Blindness could not be ensured as the raters had to go through the case notes in detail where the dosing pattern is written explicitly. The consequent bias was avoided by operationalizing certain variables and by having the rating done by three of the authors (RM, KPS and KMRP). Various definitions for clinical variables that have been used in Table 1 were according to DSM-III-R (American Psychiatric Association, 1987). Further details can be obtained from Suresh et al (1995) .
The sociodemographic arid clinical parameters were assessed as independent variables and die treatment, side effects and outcome as dependent variables. Comparisons between the two groups were effected using different statistical methods depending on the variable characteristics. Qualitative data were compared using Yates' continuity-corrected X 2 square test and Fisher's (2-tail) exact probability test. The MannWhitney U test was used when the assumptions for parametric tests were not satisfied. The independent sample t test was used to compare means of independent groups Analysis of Covariance (ANCOVA) was used to covariate out the biasing effect of total dose over serum levels between the two groups; the result was that serum lithium levels were near significantly higher in the OD group as compared with DD group (F 1, 47=3.53, p=0.066) . The data were analyzed using the Statistical Package for Social Sciences (SPSS, Ver.4.01).
RESULTS
The mean age (SD) of the sample was 33.2 (12.6) years in the OD group and 26.1 (9.5) years in the DD group. The comparison showed that the groups did not differ on any of the sociodemographicand clinical variables (Table 1) . The proportion of various categories of mood disorders in the two groups was comparable.
The mean daily (SD) lithium dose was 1003.3 (85.3) mg (range 600 -1500 mg) in the OD group and 1028.6 (221.7) mg (range 600 -1800mg) in the DD group. The mean serum level was slightly higher in the OD group (0.72+0.12 mEq/L) as compared with that in the DD group (0.65+0.19 mEq/L). The duration of follow up was 10.6+6.5 months in the OD group and 11,2+5 months in the DD group. The differences in the above parameters were not significant (Table 2) . An ANCOVA was performed to ascertain whether after covariating out the effect of the dose, the serum levels differed between the two groups. The frequency of side effects, change in dose or therapy due to side effects and need for extra treatment (e.g. addition of carbamazepine) did not differ significantly between the two groups (Table 3) . However, 3.27c of OD lithium patients had further episodes during the course of follow up, while 20Vc in the DD group had relapses. This finding just misses statistical significance. 
DISCUSSION
This is the first study in India attempting a comparative evaluation of single daily dose lithium therapy versus a divided dose regimen in the prophylaxis of mood disorders. Earlier, Surest) et al (1995) reported the use of OD lithium in acute mania. Lithium being a drug which has to be taken for a prolonged period, it is also important to explore the utility of a simpler dosage schedule in the long term management of mood disorders. This study aimed to explore such a possibility.
There are two interesting positive findings in this study. First, after correcting for dosage influences, the OD lithium schedule was found to produce higher 12-hour serum lithium levels than the DD lithium schedule. This is believed to correlate with the therapeutic efficacy of lithium. Second, the frequency of relapse was higher in the DD than in the OD lithium group. This may be because of better compliance to OD lithium but also raises a theoretical possibility of a therapeutic advantage with such a regimen. Also, the OD lithium group had higher serum lithium levels; although the mean level did not differ significantly from that of DD group, it must be kept in mind that the difference may be yet have been clinically significant.
The two groups did not differ on other outcome measures of efficacy and adverse effects. The net conclusion is that OD lithium
